Inogen Q3 revenue beats estimates

Inogen

05/11/2025 12:37

Overview

Inogen Q3 revenue grows 4% yr/yr, beating analyst expectations

Adjusted EBITDA for Q3 beats analyst estimates, reflecting improved operational performance

Company reiterates full-year revenue guidance, raises adjusted EBITDA outlook

Outlook

Inogen reiterates full-year revenue guidance of $354 mln to $357 mln

Company raises full-year adjusted EBITDA guidance to approximately $2 mln

Inogen expects Q4 revenue between $87 mln and $90 mln

Result Drivers

BUSINESS-TO-BUSINESS SALES - Increased demand from international and domestic B2B customers drove revenue growth

COST MANAGEMENT - Decrease in operating expenses due to ongoing cost management efforts

NEW PRODUCT RELEASE - Initiated limited market release of Simeox airway clearance device in the U.S.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$92.40 mln
$92.20 mln (2 Analysts)
Q3 Adjusted Net Income
Beat
-$500,000
-$5.90 mln (2 Analysts)
Q3 Net Income
-$5.30 mln
Q3 Adjusted EBITDA
Beat
$2.30 mln
$750,000 (2 Analysts)
Q3 Gross Margin
44.70%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Inogen Inc is $13.00, about 38% above its November 4 closing price of $8.06

Press Release: ID:nBwbfSmGSa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)